Cystic Fibrosis Foundation Invests in Felix Biotechnology as They Advance New Therapies Targeting Chronic Infections in Cystic Fibrosis

SOUTH SAN FRANCISCO, Calif., March 3, 2022 /PRNewswire/ -- Felix Biotechnology — a biopharmaceutical company focused on developing first-in-class, durable, antibacterial therapies to treat chronic drug-resistant infections — today announced it received a strategic investment from the...

Click to view original post